Shopping Cart
- Remove All
- Your shopping cart is currently empty
DL-AP5 (2-APV) lithium is a competitive antagonist of the NMDA (N-Methyl-D-aspartate) receptor. It exhibits notable analgesic activity and specifically blocks channels in the rabbit retina.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | DL-AP5 (2-APV) lithium is a competitive antagonist of the NMDA (N-Methyl-D-aspartate) receptor. It exhibits notable analgesic activity and specifically blocks channels in the rabbit retina. |
In vitro | DL-AP5 (100 μM) mitigates the elevation of Arc/Arg3.1 protein levels caused by glutamate exposure and reduces NMDA-induced upregulation of Arc/Arg3.1. |
In vivo | DL-AP5, when administered intra-CA1 (0-10 μg/rat), significantly diminishes NMDA's effects. At a range of 0-10 nmol via intracerebroventricular injection, it elicits a dose-dependent escalation in food intake. Moreover, a specific dose of 5 nmol of DL-AP5 via the same route effectively mitigates the reduction in food consumption that is typically prompted by an intracerebroventricular injection of ghrelin. |
Alias | DL-2-Amino-5-phosphonovaleric acid lithium, 2-APV lithium |
Molecular Weight | 203.06 |
Formula | C5H11LiNO5P |
Cas No. | 125229-62-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.